Severe Low Sugar to be Treated With Nasal Spray of Glucagon

by Colleen Fleiss on  July 28, 2019 at 8:59 PM Diabetes News
RSS Email Print This Page Comment bookmark
Font : A-A+

FDA has approved the first glucagon therapy that can be given without injection. Baqsimi, approved for patients aged 4 years and older, is the first approved glucagon therapy that can be given without an injection.
Severe Low Sugar to be Treated With Nasal Spray of Glucagon
Severe Low Sugar to be Treated With Nasal Spray of Glucagon

Approval was based on three studies — two adult studies (roughly 150 patients) and a pediatric study (roughly 50 patients) that compared a single dose of glucagon powder to a dose of injection.

Show Full Article


Efficacy and safety outcomes were similar across studies.

The drug carries a warning for patients who have conditions that might cause low levels of releasable glucose in the liver (adrenal insufficiency, chronic hypoglycemia, long periods of fasting).

Additionally, it shouldn't be given to patients with pancreatic or adrenal gland tissue tumors or sensitivities to the drug's ingredients.

Common side effects include headache, nasal congestion, nausea, upper respiratory tract irritation, vomiting, and watery eyes.

The list price for a single pack of Baqsimi is $280.80, according to the manufacturer.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Pancreas Sugar: Time to Look beyond Its Sweetness Tips for Healthy Fasting During Ramadhan Neck Cracking 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive